New version of Enzon cancer drug secures orphan status in EU

09/30/2008 | Boston Globe (tiered subscription model), The

European regulators granted orphan-drug status for Enzon Pharmaceuticals' Oncaspar-IV, a new version of its cancer drug for acute lymphoblastic leukemia. The designation prevents other drugmakers from selling copies of Oncaspar-IV for a decade should the product receive market clearance. Oncaspar-IV destroys cancer cells by depriving them of a key amino acid.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care